Business
Zydus to Acquire All Outstanding Shares of Assertio Holdings
Indian Drugmaker Expands Global Presence Through Strategic US Acquisition
Zydus Lifesciences on Wednesday announced that it will acquire US-based pharmaceutical company Assertio Holdings for a total consideration of 166.4 million US dollars, approximately ₹1,590 crore.
According to the company, Zydus Worldwide DMCC has entered into a definitive agreement through its wholly owned acquisition arm, Zara Merger Sub Inc, to acquire all outstanding shares of Assertio Holdings.
Under the agreement, Zydus will acquire the shares at 23.50 US dollars per share in cash. The transaction value has been calculated on a fully diluted basis using the treasury stock method, the company stated.
The acquisition is expected to strengthen Zydus Lifesciences’ footprint in the US pharmaceutical market and enhance its portfolio of speciality and branded medicines.
Industry experts view the deal as part of the broader strategy of Indian pharmaceutical companies to expand globally through acquisitions, partnerships, and product diversification in key international markets.
The transaction remains subject to regulatory approvals and customary closing conditions.
